Gapping up
In reaction to earnings/guidance:
- CXM +3.6%
Other news:
- MOR +7.9% (entered into equity participation and license agreements for felzartamab and MOR210)
- DAWN +7.4% (prices offering of 10 mln shares of common stock at $15.00 per share)
- HTZ +6.1% (authorizes new $2.0 bln share repurchase program)
- EVCM +3.6% (announces $50 million share repurchase program)
- ZEN +3.1% (entered into settlement talks with Jana Partners according to WSJ)
- SMFR +2.7% (announced departure of CFO Isaac Ro)
- TUSK +1.8% (announced first appeal response from FEMA related to Project Worksheet 251)
- FIVE +1.6% (approves stock repurchase program for up to $100 mln of common stock; also adds Bernard Kim to board of directors who current serves as CEO of Match Group)
- BP +1.1% (to lead and operate one of the world's largest renewables and green hydrogen energy hubs based in western Australia; to take a 40.5% stake and operatorship of the AREH project in the Pilbara Western Australia)
- WIX +1.1% (received court approval of its repurchase program pursuant to which up to $500 million of the Company's ordinary shares and/or convertible notes may be repurchased effective until December 31 2022)
- MRNA +0.8% (FDA advisory committee voted to recommend two-dose COVID-19 for children aged 6-17 years)
Analyst comments:
- SNOW +4.3% (upgraded to Buy from Hold at Canaccord Genuity)
- SPOT +3.4% (upgraded to Equal Weight from Underweight at Wells Fargo)
- SKX +1.8% (upgraded to Buy from Hold at Argus)
- TPR +1.7% (upgraded to Buy from Hold at Jefferies)
- AWI +1.4% (upgraded to Buy from Hold at Loop Capital)